Back to search

Article

Myeloid–Adaptive Response to Atezolizumab (MARTA): A Two-Gene CXCL13–CXCL8 Transcriptomic Biomarker Across Renal Cell and Urothelial Carcinoma

2026-08-24

Abstract excerpt

Transcriptomic biomarkers associated with response to immune-checkpoint blockade remain incompletely defined, particularly across tumour types. We developed Myeloid–Adaptive Response to Atezolizumab (MARTA), a two-gene transcriptomic score integrating CXCL13 and CXCL8 expression. Candidate-gene selection was performed in 81 patients receiving atezolizumab monotherapy in IMmotion150, after which MARTA was evaluated...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b00e1ea2-82dc-5b0d-a2ae-f7e966df792a
DOI
10.20944/preprints202608.1642.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Myeloid–Adaptive Response to Atezolizumab (MARTA): A Two-Gene CXCL13–CXCL8 Transcriptomic Biomarker Across Renal Cell and Urothelial CarcinomaDOI 10.20944/preprints202608.1642.v1
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.Semantic proximity
Development and Performance of a CD8 Gene Signature for Characterizing Inflammation in the Tumor Microenvironment across Multiple Tumor TypesSemantic proximity
Contribution of systemic and somatic factors to clinical response and resistance in urothelial cancer: an exploratory multi-omic analysisSemantic proximity
The Relationship of Immune Cell Signatures to Patient Survival Varies within and between Tumor TypesSemantic proximity
Translation of the 27-gene immuno-oncology test (IO Score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patientsSemantic proximity
The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohortSemantic proximity
A B cell-derived gene expression signature associates with an immunologically active tumor microenvironment and response to immune checkpoint blockade therapySemantic proximity
ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC.Semantic proximity
Integrated immuno-transcriptomic analysis of ovarian cancer identifies a four-chemokine-dominated subtype with antitumor immune-active phenotype and favorable prognosis.Semantic proximity
Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinomaSemantic proximity
A three-gene expression score for predicting clinical benefit to anti-PD-1 blockade in advanced renal cell carcinomaSemantic proximity
Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trialSemantic proximity
Select a neighboring publication to make it the new centre.